Excited for our partnership with AlamarBio Banner Health Banner Alzheimer's

We’re thrilled to share our study on diagnositc accuracy of Quanterix ALZpath and Lumipulse for #Alzheimer diagnosis- thanks to Nicholas Ashton Alessandro Padovani Virgínia Quaresma Oskar Hansson Sebastian Palmqvist Zetterberg Lab Marc Suárez-Calvet 🧠🧪 🩺🌈 and the whole team! #biomarkers

New *open access* paper in Alzheimer's & Dementia Journals — with the Alzheimer's Association #GBSC we compared 33 different plasma p-tau assays. TLDR — Plasma p-tau217 on several platforms was the best at discriminating Alzheimer’s from controls alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…

and now the paper is out... pubmed.ncbi.nlm.nih.gov/39907496/ 📣 33 different ways to measure #blood #pTau 👉Mass Spec, semi & fully-auto immunoassays 🩸#pTau217 consistently best 📈Corr. between #pTau217 assays = optimism for standardisation Jonathan Schott Ashvini Keshavan Wagner S. Brum

[#RECHERCHE #ALZHEIMER] 🧠 Clariane remet le Prix Européen Jeune Chercheur 2024 d’Fondation Recherche Alzheimer à Nicholas Ashton pour ses travaux sur le développement de tests sanguins permettant un #diagnostic ➕ précoce de la maladie. 👉 clariane.com/espace-presse/… #biomarqueurs

It was a tremendous honor to receive the Young Investigator Award from La Fondation Recherche Alzheimer (Fondation Recherche Alzheimer) earlier this month, in Paris. I am grateful for the recognition and inspired to receive my award alongside Professor Christian Haass

First panel of the DxA Day focuses on the current diagnostic landscape for Alzheimer’s - from development to implementation, featuring an expert panel les by Nicholas Ashton of Banner Health. CC Oskar Hansson, C2N Diagnostics, WashU Medicine, Beckman Coulter Life Sciences and Biogen

We're entering a new era of #Alzheimers blood testing—fully automated platforms now deliver fast, accurate #pTau217 results for use in primary & secondary care. Proud to share senior authorship and proud of this multi-centre European collaboration. 🔗 nature.com/articles/s4159…

New manuscript alert! Can blood-based biomarkers measured on a fully automated platform accurately identify Alzheimer’s disease (AD) pathology?🩸 Our new multi-cohort study has now been published in Nature Medicine: nature.com/articles/s4159…. A thread🧵

Big, big thanks to all collaborators and co-authors, especially the Gothenburg, Barcelona, and Brescia teams! Sebastian Palmqvist Noëlle Warmenhoven Nicholas Ashton Marc Suárez-Calvet 🧠🧪 🩺🌈 Oskar Hansson BioFINDER

📢Our latest study, now published in Nature Medicine , explores the potential of blood biomarkers on an automated platform to detect #Alzheimers . Plasma p-tau217 showed remarkable accuracy, with AUCs ranging from 0.93-0.96! 🩸🧠 Read more here: nature.com/articles/s4159…

Our comments on the new #blood tests for #Alzheimers #disease which are increasingly improving and becoming applicable to clinical use. We should use them but use them in the correct way. nature.com/articles/d4158…

The boss is in town! 🇸🇪 Come and join our free lecture with Professor Henrik Zetterberg, the world leader in biomarkers for hashtag #Alzehimers disease, hosted at the Biodesign Institute at Arizona State University and Banner Health on Monday 28th April!

I’m proud to share the first PhD paper of my first (formally) PhD student Ilaria Pola, where we investigated proteins associated with TSPO PET imaging. 🥳 We are now already working on the extension of this work, so stay tuned! 🧠💧🩸 Nicholas Ashton McGill University

Immunoassay choice for #pTau217 is important! In this study, we show that LMW #pTau217 is more specific to Alzheimers pathology than HMW #pTau217 immunoassay designs – which can give false-positives. alz-journals.onlinelibrary.wiley.com/doi/10.1002/al… BioFINDER Oskar Hansson

There she goes....😢 The Goodison montage on Football Focus #Everton

Biomarkers of AD-related #neuroinflammation are missing from our toolbox for patient evaluation and research. This great work by Andrea L. Benedet start to see a change in that tide. alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…

Fluid biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay AlamarBio Andrea L. Benedet alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…

NPTX2 is emerging as a key neurodegeneration biomarker, but measurement tools are limited. We developed a low-volume, automated Simoa assay for its quantification in CSF #biomarkers #neurodegeneration pubmed.ncbi.nlm.nih.gov/40522075/

We developed a #CSF assay for #SV2A and found it correlates strongly with UCB-J PET in Alzheimers—more so than other established CSF synaptic markers. A promising step toward fluid biomarkers of #synaptic density #biomarkers #neurodegeneration pubmed.ncbi.nlm.nih.gov/40491249/